For scientific and diagnostic laboratories, a secure supply chain for high-quality reagents is critical for weathering unforeseen circumstances such as the COVID-19 pandemic. Historically, recombinant antibody technology has been reserved for companies developing novel biologics. The technology mitigates manufacturing and supply risks by “digitizing” antibody assets and guaranteeing long-term reproducible production. Recombinant technology also increases the ability to engineer existing antibodies for any specific bio-physical requirements that might arise, as producing antibodies by transient transfection enables rapid reformatting.
In this webinar brought to you by Sartorius, Nicholas Hutchings will describe how recombinant antibody technology came to the rescue during the COVID-19 pandemic. COVID-19 antibodies were quickly produced and tested in a variety of formats so that researchers would have the tools they needed to investigate the virus and develop diagnostic assays and treatments. This process can be mimicked for future emergency scenarios to speed up pandemic responses.
Topics to be covered
Securing the antibody supply chain
Recombinant antibodies for rapid emergency response
The importance of recombinant antibody technology during the COVID-19 pandemic
Wednesday, May 19, 2021
12:00 - 1:00 PM Eastern Time
Meet the speaker
Nicholas Hutchings, PhD CEO Absolute Antibody, Ltd.
Sponsored by
Register Now
TS_WEBINARSIGNUP_LabTools_Sartorius_Securing the Antibody Supply Chain through Recombinant Antibody Technology: A COVID-19 Case Study May 19, 2021
You must have Javascript and Cookies enabled to access this webcast.
Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
